'Biologics': A clinically meaningless term

British Journal of Dermatology

Volumn 154, Issue 5, 2006, Pages 809-812

  Katz, Kenneth A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTITOXIN; ARSPHENAMINE; BIOLOGICAL PRODUCT; COLONY STIMULATING FACTOR; CYCLOSPORIN; CYTOKINE; DENILEUKIN DIFTITOX; DIPHTHERIA PERTUSSIS TETANUS VACCINE; EFALIZUMAB; HYBRID PROTEIN; INFLIXIMAB; INTERFERON; METHOTREXATE; POLYLACTIC ACID; TUMOR NECROSIS FACTOR; VACCINE;

ANAPHYLAXIS; CLINICAL TRIAL; CONTINUING EDUCATION; COST EFFECTIVENESS ANALYSIS; DRUG FATALITY; DRUG LABELING; DRUG MECHANISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EDITORIAL; HEMOLYTIC ANEMIA; HUMAN; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; UNSPECIFIED SIDE EFFECT;

BIOLOGICAL PRODUCTS; DERMATOLOGIC AGENTS; HUMANS; LEGISLATION, DRUG; TERMINOLOGY; UNITED STATES;

EID: 33645822785     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07225.x     Document Type: Editorial

References (29)

1. Allen W. Love and Death. [movie] Hollywood (California): United Artists 1975
2. Katz KA. AMEVIVE's advertisements: problematic? [letter]. Arch Dermatol 2005 141 1602 4.
3. National Psoriasis Foundation [homepage on the internet]. Portland, OR NPF, c. 2005 [updated February 2005; cited 3 October 2005]. ABOUT BIOLOGICS [about 2 screens] ( http://www.psoriasis.org/treatment/psoriasis/biologics/ about.php )
4. Callen JP. New psoriasis treatments based upon a deeper understanding of the pathogenesis of psoriasis vulgaris and psoriatic arthritis: a personal appraisal of their use in practice. J Am Acad Dermatol 2003 49 351 6.
5. Kipnis CD Myers WA Opeola M Gottlieb AB. Biologic treatments for psoriasis. J Am Acad Dermatol 2005 52 671 82.
6. Krueger G Ellis CN. Psoriasis - recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 2005 53 S94 100.
7. Lebwohl M. A clinician's paradigm in the treatment of psoriasis. J Am Acad Dermatol 2005 53 S59 69.
8. Menter MA Krueger GC Feldman SR Weinstein GD. Psoriasis treatment 2003 at the new millennium: position paper on behalf of the authors. J Am Acad Dermatol 2003 49 S39 43.
9. Thomas VD Yang FC Kvedar JC. Biologics in psoriasis: a quick reference guide. J Am Acad Dermatol 2005 53 346 51.
10. Mehlis SL Gordon KB. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol 2003 49 S44 50.
11. Kenimer JG Jessop JJ. Biologics. In FDA Regulatory Affairs: a Guide For Prescription Drugs, Medical Devices, and Biologics Pisano DJ Mantus D eds Boca Raton CRC Press 2004 129 52.
12. Biological Products General. 21 C.F.R. Sect. 600.3 2005
13. Callen JP Kulp-Shorten CL Wolverton SE. Methotrexate. In Comprehensive Dermatologic Drug Therapy Wolverton SE ed. Philadelphia W.B. Saunders Company 2001 147 64.
14. Koo JYM Lee CS Maloney JE. Cyclosporine and related drugs. In Comprehensive Dermatologic Drug Therapy Wolverton SE ed. Philadelphia W.B. Saunders Company 2001 205 29.
15. U.S. Food and Drug Administration [homepage on the internet]. Washington DC: FDA/CDER/Office of Drug Safety [updated 30 September 2005; cited 3 October 2005]. 2005 Safety Alerts for Drugs, Biologics, Medical Devices, and Dietary Supplements - Raptiva (efalizumab) [about 50 screens] ( http://www.fda.gov/ medwatch/safety/2005/safety05.htm #Raptiva)
16. Bagel J Garland WT Breneman D et al. Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial. J Am Acad Dermatol 1998 38 938 44.
17. Gamerman GE Mackler BF Landa MM. '1996' starting the modern era of biologics regulation: FDA's elimination of establishment licensure and other changes. Biotechnol Appl Biochem 1997 25 189 95.
18. Pisano DJ. Overview of drug development and the FDA. In FDA Regulatory Affairs: a Guide for Prescription Drugs, Medical Devices, and Biologics Pisano DJ Mantus D eds Boca Raton CRC Press 2004 1 20.
19. Beatrice M. FDA regulatory reform. Curr Opin Biotechnol 1997 8 370 8.
20. U.S. Food and Drug Administration. Biological products: reporting of biological product deviations in manufacturing. Food and Drug Administration, HHS. Final rule. Federal Register 7 November 2000 65 66621 35.
21. Cournoyer D Toffelmire EB Wells GA et al. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. J Am Soc Nephrol 2004 15 2728 34.
22. Asher DM. The transmissible spongiform encephalopathy agents: concerns and responses of United States regulatory agencies in maintaining the safety of biologics. Dev Biol Stand 1999 100 103 18.
23. Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 2004 102 177 93.
24. Baert F Noman M Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003 348 601 8.
25. U.S. Food and Drug Administration [homepage on the internet]. Washington DC: FDA/Center for Devices and Radiological Health [updated 20 August 2004; cited 4 October 2005]. Approval letter for Sculptra [about 3 screens] ( http://www.fda.gov/cdrh/pdf3/p030050a.pdf )
26. Hankin CS Feldman SR Szczotka A et al. A cost comparison of treatments of moderate to severe psoriasis. Drug Benefit Trends 2005 17 200 14.
27. Anti-TNF Therapies for the Treatment of Psoriasis and Psoriatic Arthritis: a Local CME Dinner Meeting Series Based on the Latest Clinical Findings Regarding Biologic Therapies [brochure]. Norwalk, CT Educational Awareness Solutions 2005
28. Callen JP Krueger GG Lebwohl M et al. AAD consensus statement on psoriasis therapies. J Am Acad Dermatol 2003 49 897 9.
29. Gordon KB West DP. Biologic therapy in dermatology. In Comprehensive Dermatologic Drug Therapy Wolverton SE ed.